SEGMENT INFORMATION - Company`s Segment, Including Segment Expenses, and A Reconciliation to Net Income (Loss) (Details) - USD ($) $ in Thousands		3 Months Ended						9 Months Ended
		Sep. 30, 2026	Jun. 30, 2026	Mar. 31, 2026	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2026	Sep. 30, 2025
Segment Reporting [Line Items]
Total revenues		$ 381,351			$ 399,356			$ 1,513,405	$ 1,755,303
Segment expenses and other segment items
Cost of sales (excluding amortization of in-licensed rights)		188,512			150,775			446,665	440,897
Restructuring Charges		0			40,510			0	40,510
Selling, general and administrative- other (excluding non-cash items)		118,612			91,893			335,163	363,419
Gain on debt extinguishment		0			3,761			0	3,761
Loss (gain) on strategic investments		(523)			36,739			(2,683)	(17,268)
Interest expense		21,616			9,460			64,837	19,191
Interest income		7,086			7,249			19,653	22,693
Income tax expense (benefit)		2,695			(14,102)			18,051	6,634
Depreciation and amortization expense								26,903	39,268
Stock-based compensation expense								80,614	93,380
Litigation contingency charge		0			0			39,000	0
Net Income (Loss)		(28,461)	$ (4,890)	$ 330,959	(50,568)	$ 196,892	$ (447,508)	297,608	(301,184)
Reconciliation of profit or loss
Adjustments and reconciling items		0			0			0	0
Net (loss) income - basic		(28,461)	$ (4,890)	$ 330,959	(50,568)	$ 196,892	$ (447,508)	297,608	(301,184)
Operating Segments [Member]
Segment expenses and other segment items
Cost of sales (excluding amortization of in-licensed rights)		188,512			150,775			446,665	440,897
Compensation and other personnel expenses		62,644			44,428			185,299	227,351
Up-front and Collaboration License Fees		0			100,000			50,000	683,787
Manufacturing expenses		2,251			33,897			23,846	182,047
Clinical trial expenses		20,511			28,613			61,917	95,271
Facility- and technology-related expenses (excluding depreciation and amortization)		22,940			20,577			69,772	76,814
Restructuring Charges		0			40,510			0	40,510
Research and development- other (excluding non-cash items)	[1]	17,241			20,883			55,759	81,197
Selling, general and administrative- other (excluding non-cash items)	[2]	50,787			41,883			133,442	149,347
Roche Collaboration Reimbursement		(7,138)			(12,198)			(22,496)	(66,368)
Other segment items	[3]	1,673			(430)			(842)	(3,653)
Gain on debt extinguishment		0			(3,761)			0	(3,761)
Loss (gain) on strategic investments		523			(36,739)			2,683	17,268
Interest expense		21,616			9,460			64,837	19,191
Interest income		(7,086)			(7,249)			(19,653)	(22,693)
Income tax expense (benefit)		2,695			(14,102)			18,051	6,634
Depreciation and amortization expense		5,900			18,450			26,903	39,268
Stock-based compensation expense		26,743			14,927			80,614	93,380
Litigation contingency charge		$ 0			$ 0			$ 39,000	$ 0

[1] Research and development-other includes professional services, pre-clinical expenses and research and other expenses.

[2] Selling, general and administrative-other includes professional services and other expenses.

[3] Other segment items included in segment net (loss) income include accretion of investment discount, net and other, net, as well as items separately presented and not defined as significant expenses below. Significant expense categories that are regularly provided to the CODM include cost of sales (excluding amortization of in-licensed rights), compensation and other personnel expenses, up-front and collaboration license fees, manufacturing expenses, clinical trial expenses, facility- and technology-related expenses, restructuring charge, research and development- other and selling, general and administrative- other. The other expense or income information are other segment items and include separate presentation of loss (gain) on strategic investments, interest expense, interest income, income tax expense (benefit), depreciation and amortization, stock-based compensation expense and litigation settlement charge, which are included in the measure of segment net (loss) income, but are not significant segment expenses.